{"success":true,"data":{"pressRelease":{"id":"133344","rtpr_id":"nGNX2cxz9c","ticker":"ALCOX","exchange":"Euronext Paris","all_tickers":["ALCOX"],"title":"Nicox Announces Extension of Cash Runway","author":"Globe Newswire","published_at":"2026-09-02T05:30:00.286Z","article_body":"Press Release \n Nicox Announces Extension of Cash Runway \n * Cash position, of €8.4 million (1)as of 31 August 2026, sufficient to fund existing operations beyond Q1 2028 \n * NCX 470 U.S. NDA approval milestone would fund operations into 2029, while subsequent royalties could extend the cash runway substantially further \n * Discussions on future strategic opportunities continuing \n September 2, 2026 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced an extension of its cash runway and provided a corporate and financial update. The PDUFA date (2)for NCX 470 in the United States was announced (https://www.nicox.com/wp-content/uploads/EN_NCX470PDUFADateSeptember2026_PR_FINAL.pdf)on 27 August. “Our current level of cash provides visibility for over 18 months, and our e \n xclusive U.S. partner, Kowa, anticipates a commercial launch of NCX 470, subject to approval, in H2 2027 . The expected NDA approval milestone supports us into 2029, with subsequent royalty revenue extending financial visibility well beyond that. With NCX 470 moving through the regulatory review period in two major markets, we are in a financially solid position to support our partners’ regulatory and pre-commercialisation activities whilst increasingly focussing our experienced team on evaluating future \n growth opportunities.” said Gavin Spencer, Chief Executive Officer of Nicox. Cash Runway As of 31 August 2026, Nicox had estimated cash and cash equivalents of €8.4 million (1), compared to €4.1 million as of 31 December 2025. The Company has significantly reduced its fixed costs and, based on its current structure and operations, estimates that its cash position is sufficient to fund existing operations beyond Q1 2028. The receipt of the milestone payable upon approval of the NCX 470 in the U.S. (PDUFA \n date (2)30 April 2027) would fund existing operations into 2029, while subsequent royalties expected following U.S. launch in H2 2027 could extend the cash runway substantially further. Additional financing options remain available under the Vester Finance shareholder loan announced (https://www.nicox.com/wp-content/uploads/EN_VesterShareholderLoanJune2026_PR_FINAL.pdf)in June 2026. The Company remains committed to cost control and optimizing resource allocation to support our strategic objectives. If any \n of the assumptions around estimated income, debt or costs change, this may impact the estimated cash runway. In parallel, the Company is pursuing business development discussions and continuing to evaluate several strategic growth opportunities, including potential collaborations or business combinations. Management Update Doug Hubatsch, Nicox’s EVP, Head of Research and Development and Chief Scientific Officer since December 2021, has assumed the new position of Chief Scientific Advisor, \n transitioning away from operational management. In this role, he will continue to support NCX 470 through the NDA review period, as well as advise the Company on growth opportunities and scientific strategy. Siobhan Garbutt, VP and Head of Clinical Development, will assume leadership of the development team and will continue to support Nicox’s partners during the NDAs review process while also contributing to the evaluation of future development opportunities for the Company. Siobhan has been with Nicox \n since July 2022 and has led the NCX 470 clinical activities, as well as playing a major role in writing the NDA. She has close to 20 years of clinical development experience, the majority of it in ophthalmology, and has worked in large pharma, biotech and CRO settings. We thank Doug for his leadership in driving NCX 470 to NDA submission and we congratulate Siobhan on taking on this expanded role in the Company. “I would like to take the opportunity to thank Doug Hubatsch, who has led the Development \n team so strongly through the later stages of the NCX 470 clinical program, and has played a key role in building lasting partnerships with Kowa and Ocumension. Doug has now assumed the role of Chief Scientific Advisor and we are pleased that he will continue to contribute his expertise to Nicox, supporting through the NCX 470 NDA review period and advising on scientific strategy and future growth opportunities. Siobhan Garbutt, VP Clinical Development, who has worked closely with Doug since joining Nicox in \n 2022, will assume leadership of the development function and will be working closely with the rest of the Nicox team on defining the future,” added Gavin Spencer, Chief Executive Officer of Nicox . \n About Nicox \n Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead late-stage development program is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world. Nicox also has a preclinical \n research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, \n headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX). For more information www.nicox.com \n\n\n\n Analyst coverage \n H.C. Wainwright & Co Yi Chen New York, U.S. \n The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. \n\n\n\n Contacts \n Nicox Gavin Spencer Chief Executive Officer T +33 (0)4 97 24 53 00 communications@nicox.com Media Sophie Baumont Rose Piquante Consulting T +33 6 27 74 74 49 sophie.baumont@rosepiquante-consulting.com \n Disclaimer \n The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, \n officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “ Rapport Annuel 2025 ” which are available on Nicox’s website (www.nicox.com). Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall \n prevail. \n Nicox S.A. Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, France T +33 (0)4 97 24 53 00 \n\n\n\n1 Unaudited estimate prepared by management based on information available as\nof the date of this press release. The Company’s next reporting will be the\nfirst half 2026 accounts in October 2026.\n\n2 A PDUFA date is the target date by which the U.S. Food and Drug\nAdministration (FDA) aims to complete its review and issue a decision on a New\nDrug Application (NDA) under the Prescription Drug User Fee Act (PDUFA).\n\nAttachment\n* EN_CorporateUpdateSeptember2026_PR_FINAL\n(https://ml-eu.globenewswire.com/Resource/Download/66d67f09-e372-4b39-9e2c-02f7ff710e99)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c4c68e53-e467-4048-b580-d1596c4d6d8e)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX2cxz9c","title":"Nicox Announces Extension of Cash Runway","author":"Globe Newswire","ticker":"ALCOX","created":"2026-09-02T05:30:00.286Z","tickers":["ALCOX"],"exchange":"Euronext Paris","article_body":"Press Release \n Nicox Announces Extension of Cash Runway \n * Cash position, of €8.4 million (1)as of 31 August 2026, sufficient to fund existing operations beyond Q1 2028 \n * NCX 470 U.S. NDA approval milestone would fund operations into 2029, while subsequent royalties could extend the cash runway substantially further \n * Discussions on future strategic opportunities continuing \n September 2, 2026 – release at 7:30 am CET Sophia Antipolis, France Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced an extension of its cash runway and provided a corporate and financial update. The PDUFA date (2)for NCX 470 in the United States was announced (https://www.nicox.com/wp-content/uploads/EN_NCX470PDUFADateSeptember2026_PR_FINAL.pdf)on 27 August. “Our current level of cash provides visibility for over 18 months, and our e \n xclusive U.S. partner, Kowa, anticipates a commercial launch of NCX 470, subject to approval, in H2 2027 . The expected NDA approval milestone supports us into 2029, with subsequent royalty revenue extending financial visibility well beyond that. With NCX 470 moving through the regulatory review period in two major markets, we are in a financially solid position to support our partners’ regulatory and pre-commercialisation activities whilst increasingly focussing our experienced team on evaluating future \n growth opportunities.” said Gavin Spencer, Chief Executive Officer of Nicox. Cash Runway As of 31 August 2026, Nicox had estimated cash and cash equivalents of €8.4 million (1), compared to €4.1 million as of 31 December 2025. The Company has significantly reduced its fixed costs and, based on its current structure and operations, estimates that its cash position is sufficient to fund existing operations beyond Q1 2028. The receipt of the milestone payable upon approval of the NCX 470 in the U.S. (PDUFA \n date (2)30 April 2027) would fund existing operations into 2029, while subsequent royalties expected following U.S. launch in H2 2027 could extend the cash runway substantially further. Additional financing options remain available under the Vester Finance shareholder loan announced (https://www.nicox.com/wp-content/uploads/EN_VesterShareholderLoanJune2026_PR_FINAL.pdf)in June 2026. The Company remains committed to cost control and optimizing resource allocation to support our strategic objectives. If any \n of the assumptions around estimated income, debt or costs change, this may impact the estimated cash runway. In parallel, the Company is pursuing business development discussions and continuing to evaluate several strategic growth opportunities, including potential collaborations or business combinations. Management Update Doug Hubatsch, Nicox’s EVP, Head of Research and Development and Chief Scientific Officer since December 2021, has assumed the new position of Chief Scientific Advisor, \n transitioning away from operational management. In this role, he will continue to support NCX 470 through the NDA review period, as well as advise the Company on growth opportunities and scientific strategy. Siobhan Garbutt, VP and Head of Clinical Development, will assume leadership of the development team and will continue to support Nicox’s partners during the NDAs review process while also contributing to the evaluation of future development opportunities for the Company. Siobhan has been with Nicox \n since July 2022 and has led the NCX 470 clinical activities, as well as playing a major role in writing the NDA. She has close to 20 years of clinical development experience, the majority of it in ophthalmology, and has worked in large pharma, biotech and CRO settings. We thank Doug for his leadership in driving NCX 470 to NDA submission and we congratulate Siobhan on taking on this expanded role in the Company. “I would like to take the opportunity to thank Doug Hubatsch, who has led the Development \n team so strongly through the later stages of the NCX 470 clinical program, and has played a key role in building lasting partnerships with Kowa and Ocumension. Doug has now assumed the role of Chief Scientific Advisor and we are pleased that he will continue to contribute his expertise to Nicox, supporting through the NCX 470 NDA review period and advising on scientific strategy and future growth opportunities. Siobhan Garbutt, VP Clinical Development, who has worked closely with Doug since joining Nicox in \n 2022, will assume leadership of the development function and will be working closely with the rest of the Nicox team on defining the future,” added Gavin Spencer, Chief Executive Officer of Nicox . \n About Nicox \n Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead late-stage development program is NCX 470 (bimatoprost grenod), a novel nitric oxide-donating bimatoprost eye drop, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension, licensed to Ocumension Therapeutics for the Chinese, Korean and Southeast Asian markets and to Kowa in the rest of the world. Nicox also has a preclinical \n research program on NCX 1728, a nitric oxide-donating phosphodiesterase-5 inhibitor, with Glaukos. Nicox’s first product, VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, is available commercially in the U.S. and over 15 other territories. Nicox generates revenue from ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Harrow, Inc. in the U.S., and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets. Nicox, \n headquartered in Sophia Antipolis, France, is listed on Euronext Growth Paris (Ticker symbol: ALCOX). For more information www.nicox.com \n\n\n\n Analyst coverage \n H.C. Wainwright & Co Yi Chen New York, U.S. \n The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports. \n\n\n\n Contacts \n Nicox Gavin Spencer Chief Executive Officer T +33 (0)4 97 24 53 00 communications@nicox.com Media Sophie Baumont Rose Piquante Consulting T +33 6 27 74 74 49 sophie.baumont@rosepiquante-consulting.com \n Disclaimer \n The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, \n officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements. Risks factors which are likely to have a material effect on Nicox’s business are presented in section 3 of the “ Rapport Annuel 2025 ” which are available on Nicox’s website (www.nicox.com). Finally, this press release may be drafted in the French and English languages. If both versions are interpreted differently, the French language version shall \n prevail. \n Nicox S.A. Sundesk Sophia Antipolis, Bâtiment C, Emerald Square, Rue Evariste Galois, 06410 Biot, France T +33 (0)4 97 24 53 00 \n\n\n\n1 Unaudited estimate prepared by management based on information available as\nof the date of this press release. The Company’s next reporting will be the\nfirst half 2026 accounts in October 2026.\n\n2 A PDUFA date is the target date by which the U.S. Food and Drug\nAdministration (FDA) aims to complete its review and issue a decision on a New\nDrug Application (NDA) under the Prescription Drug User Fee Act (PDUFA).\n\nAttachment\n* EN_CorporateUpdateSeptember2026_PR_FINAL\n(https://ml-eu.globenewswire.com/Resource/Download/66d67f09-e372-4b39-9e2c-02f7ff710e99)\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/c4c68e53-e467-4048-b580-d1596c4d6d8e)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-02T05:30:00.321063436Z","server_sent_at_ms":1788327000321},"received_at":"2026-09-02T05:30:00.429Z","source_url":"https://www.globenewswire.com/news-release/2026/09/02/3354826/0/en/nicox-announces-extension-of-cash-runway.html"},"analysis":{"id":"122239","press_release_id":"133344","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Runway extension is contingent on receiving the NCX 470 approval milestone in 2027","Cash figures are unaudited management estimates","Reliance on strategic opportunities for long-term growth"],"eventType":"operations_update","narrative":"Nicox increased its cash position to €8.4 million as of August 31, 2026, extending its estimated runway to fund existing operations beyond Q1 2028.\n\nThe company announced a PDUFA date of April 30, 2027 for NCX 470, noting that the expected approval milestone would fund operations into 2029.\n\nDoug Hubatsch transitioned to Chief Scientific Advisor, while Siobhan Garbutt assumed leadership of the development team to support the NDA review.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Cash runway extended into 2028, with visibility into 2029 hinging on NCX 470 approval next April."},"keyFigures":{"customDimensions":{"pdufa_date":"April 30, 2027","runway_current":"beyond Q1 2028","cash_position_eur":"€8.4 million","runway_with_milestone":"into 2029","cash_position_dec_2025_eur":"€4.1 million"}},"quotedText":"The expected NDA approval milestone supports us into 2029, with subsequent royalty revenue extending financial visibility well beyond that.","namedEntities":{"people":[{"name":"Gavin Spencer","role":"Chief Executive Officer"},{"name":"Doug Hubatsch","role":"Chief Scientific Advisor"},{"name":"Siobhan Garbutt","role":"VP and Head of Clinical Development"}],"products":["NCX 470","NCX 1728","VYZULTA","ZERVIATE"],"companies":[{"name":"Kowa","relationship":"partner"},{"name":"Ocumension Therapeutics","relationship":"partner"},{"name":"Glaukos","relationship":"partner"},{"name":"Bausch + Lomb","relationship":"partner"},{"name":"Harrow, Inc.","relationship":"partner"},{"name":"Vester Finance","relationship":"debt provider"},{"name":"H.C. Wainwright & Co","relationship":"analyst"}],"dollarAmounts":[{"amount":"€8.4 million","context":"cash position as of 31 August 2026"},{"amount":"€4.1 million","context":"cash position as of 31 December 2025"}]},"materialImpact":{"score":3,"reasoning":"Cash runway extended significantly to beyond Q1 2028, alleviating immediate solvency risks for a small-cap biotech. The update also includes a concrete PDUFA date, which serves as a near-term binary catalyst, and material management restructuring."},"tickerRelevance":{"others":[],"primary":"ALCOX"},"globalImportance":20,"audienceRelevance":10,"eventTypeSecondary":["executive_change"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"mid","sectorWeight":"biotech"}},"event_type":"operations_update","event_type_secondary":["executive_change"],"sentiment":"bullish","material_impact_score":3,"narrative":"Nicox increased its cash position to €8.4 million as of August 31, 2026, extending its estimated runway to fund existing operations beyond Q1 2028.\n\nThe company announced a PDUFA date of April 30, 2027 for NCX 470, noting that the expected approval milestone would fund operations into 2029.\n\nDoug Hubatsch transitioned to Chief Scientific Advisor, while Siobhan Garbutt assumed leadership of the development team to support the NDA review.","key_figures":{"customDimensions":{"pdufa_date":"April 30, 2027","runway_current":"beyond Q1 2028","cash_position_eur":"€8.4 million","runway_with_milestone":"into 2029","cash_position_dec_2025_eur":"€4.1 million"}},"named_entities":{"people":[{"name":"Gavin Spencer","role":"Chief Executive Officer"},{"name":"Doug Hubatsch","role":"Chief Scientific Advisor"},{"name":"Siobhan Garbutt","role":"VP and Head of Clinical Development"}],"products":["NCX 470","NCX 1728","VYZULTA","ZERVIATE"],"companies":[{"name":"Kowa","relationship":"partner"},{"name":"Ocumension Therapeutics","relationship":"partner"},{"name":"Glaukos","relationship":"partner"},{"name":"Bausch + Lomb","relationship":"partner"},{"name":"Harrow, Inc.","relationship":"partner"},{"name":"Vester Finance","relationship":"debt provider"},{"name":"H.C. Wainwright & Co","relationship":"analyst"}],"dollarAmounts":[{"amount":"€8.4 million","context":"cash position as of 31 August 2026"},{"amount":"€4.1 million","context":"cash position as of 31 December 2025"}]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-02T05:33:02.374Z","global_importance":20,"audience_relevance":10,"importance_components":{"tickerTier":"small-cap","eventGravity":"mid","sectorWeight":"biotech"}},"durationMs":181932,"modelName":"glm-4.7"}}